Compound reference
Semaglutide Dosage Guide 2026: Clinical Trials vs Reported Use
Short answer
What it is: semaglutide is a GLP-1 receptor agonist, once-weekly as an injection, FDA approved as Ozempic (type 2 diabetes), Wegovy (weight management), and Rybelsus (daily oral tablets).
The trial dose: the big obesity trial, STEP 1 (Wilding, NEJM 2021), tested one maintenance dose over 68 weeks:
- 2.4mg once weekly
- reached over 16 weeks: 0.25mg, 0.5mg, 1mg, 1.7mg, then 2.4mg
The headline number: mean body weight came down 14.9% at 68 weeks, against 2.4% on placebo.
The catch: doses are written in milligrams. Syringes read in units.
Why it trips people: they only reconcile once you know a vial's concentration.
The real risk: FDA has logged adverse-event reports tied to dosing errors, some requiring hospitalization, from self-measured compounded doses. That mismatch, not the milligrams, is behind the dosing errors FDA has logged.
The status: FDA approved under brand names; research-grade vials are not the approved product. Every trial figure on this page comes straight from the cited papers, DOIs at the bottom.
The calculator
How it works: type in a vial size, a water amount, a syringe type, and a dose in milligrams. It gives back the concentration, the volume, and the unit reading.
Units converter
Converts the numbers you type. It does not recommend a dose.
Arithmetic only. Check the result against your own vial, your own reconstitution, and your own syringe before you trust any unit count.
The Decadewise briefing
One compound, one paper, or one piece of math like this, every week. Free.
Education only. Unsubscribe anytime.
On this page
Community reports, not a protocol
What do people report running?
The source: what follows is what community posts describe, labeled as exactly that.
The products posted: research-grade vials in 2mg, 5mg, and 10mg sizes, bacteriostatic water, and insulin syringes, discussed right alongside the brand pens.
The recurring questions: the same ones that fill the search suggestions: how many units is a given milligram amount, how many doses are in a 2mg vial, what the reconstitution formula is.
The schedules reported: posters describe copying the label-style escalation, starting at 0.25mg and stepping up every few weeks. Others describe holding at a lower dose to stretch a vial.
The arithmetic pressure: a 5mg vial holds two 2.4mg maintenance doses and little else. A 2mg vial does not cover even one.
The confusion is real: FDA has received reports of dosing errors from people measuring their own compounded semaglutide, some requiring hospitalization.
What this section is: a summary of reported behavior, none of it verified the way trial data is. Community reports, not a protocol.
Peer-reviewed trial data
What did the trials do?
The setup: STEP 1 (Wilding et al., New England Journal of Medicine, 2021) enrolled 1,961 adults with obesity, or overweight with a weight-related condition, and no diabetes. They were randomized 2:1 to once-weekly semaglutide 2.4mg or placebo for 68 weeks, plus lifestyle intervention.
The escalation: nobody started at 2.4mg. The trial escalated over 16 weeks, and the current Wegovy label prints the same schedule.
| Weeks | Weekly dose | Phase |
|---|---|---|
| 1 to 4 | 0.25mg | start |
| 5 to 8 | 0.5mg | escalation |
| 9 to 12 | 1mg | escalation |
| 13 to 16 | 1.7mg | escalation |
| 17 onward | 2.4mg | maintenance |
Why steps matter: the slow ramp exists to reduce gastrointestinal adverse reactions, per the label. The trial data below shows what the ramp leads to.
The result: mean body weight came down 14.9% at 68 weeks on 2.4mg, against 2.4% on placebo. In kilograms, that was 15.3kg versus 2.6kg.
The thresholds: 86.4% of the semaglutide group lost at least 5% of body weight, against 31.5% on placebo. Half the semaglutide group lost 15% or more.
The diabetes trial: STEP 2 (Davies et al., The Lancet, 2021) ran 1,210 people with type 2 diabetes for 68 weeks. Weight came down 9.6% on 2.4mg against 3.4% on placebo.
The long run: STEP 5 (Garvey et al., Nature Medicine, 2022) followed 304 people for 104 weeks: down 15.2% against 2.6% on placebo. Gastrointestinal adverse events were far more frequent on semaglutide, 82.2% against 53.9%, mostly mild to moderate.
The stopping data: in the STEP 1 extension, one year after treatment stopped, participants had regained two-thirds of the weight they lost.
The heart trials: SUSTAIN-6 (Marso et al., NEJM, 2016) tested 0.5mg and 1.0mg in 3,297 people with type 2 diabetes; the cardiovascular composite came in lower on semaglutide, hazard ratio 0.74, but retinopathy complications ran higher, hazard ratio 1.76. SELECT (Lincoff et al., NEJM, 2023) tested 2.4mg in 17,604 people with cardiovascular disease and overweight or obesity, no diabetes; major cardiovascular events hit 6.5% versus 8.0% on placebo, hazard ratio 0.80.
Don't merge these numbers: different populations, different doses, different endpoints.
14.9%
mean body weight down at 68 weeks, 2.4mg arm
2.4%
on placebo at 68 weeks
86.4%
lost at least 5% of body weight, versus 31.5% on placebo
1,961
people enrolled in STEP 1
STEP 1 obesity trial, Wilding et al., NEJM 2021.
Does the trial dose match the internet dose?
The usual dodge: most pages we've read either sidestep the question or hand you a schedule with no trial behind it. We're doing neither.
What the trial's schedule is for
What it's for: semaglutide is the odd case where the trial dose became the label dose. The 16 week ramp to 2.4mg was built to test one fixed target dose while limiting gastrointestinal side effects, and the FDA-approved label now prints that same ramp.
What it is: a research protocol turned prescribing label, written for the approved pens. Not a recommendation for anything that comes in a vial.
What people run online
What the posts show: people describe reconstituting research vials and copying the label ramp on their own, compressing the steps, or holding low to stretch supply. None of those patterns has been studied in a controlled trial, as of our 20 July 2026 check.
The cost logic posted: a 5mg vial is two maintenance doses, so the posted logic pushes toward less per week. Tolerance varies enough that two people on the same nominal schedule report very different real doses.
We are not going to pick one of those numbers for you.
The real question: it is really about your body, your risk tolerance, and a conversation with a doctor who knows your history. What we can give you is the published trials and the math behind a dose; the rest belongs to you and someone qualified.
How does the units math work?
The point: here is the arithmetic, done once, in general terms, attached to nobody's dose.
Example one: say a 5mg vial gets reconstituted with 1mL of bacteriostatic water. That's 5mg per mL, or 5,000mcg per mL.
The syringe side: on a U-100 insulin syringe, 100 units fill a mL, so each unit is 1/100th of a mL, which at this concentration is 50mcg, or 0.05mg. From there: 0.25mg is 5 units, 1mg is 20 units, 2.4mg is 48 units.
Change one thing: a 10mg vial with the same 1mL of water. Concentration doubles to 10mg per mL.
What changes: each unit now equals 0.1mg instead of 0.05mg. The same 2.4mg is now 24 units, not 48, and 0.25mg is 2.5 units.
The forum trap: that "20 units" someone read on a forum could be 1mg at one concentration and 2mg at another.
| Vial | Concentration | 1 unit equals | What the article works out |
|---|---|---|---|
| 5mg + 1mL | 5mg per mL (5,000mcg per mL) | 0.05mg (50mcg) | 0.25mg is 5 units, 1mg is 20 units, 2.4mg is 48 units |
| 10mg + 1mL | 10mg per mL | 0.1mg | 0.25mg is 2.5 units, 2.4mg is 24 units, not 48 |
| Syringe | Units per mL | 1 unit equals |
|---|---|---|
| U-100 | 100 units per mL | 0.01mL |
| U-40 | 40 units per mL | 0.025mL |
Trap two: not the concentration, the syringe. Insulin syringes read in units at two scales.
The two scales: U-100: 100 units per mL, so a unit is 0.01mL. U-40: 40 units per mL, so a unit is 0.025mL.
The 2.5x problem: use a U-40 with U-100 numbers in your head and every unit is 2.5 times the volume you meant. Same vial, same concentration, same "20 units" on the barrel.
Look at the barrel in your hand first; the concentration math is wrong without it.
The pen exception: the approved pens come pre-filled at fixed doses, so there is no reconstitution and no unit conversion. The units math only enters with vials and syringes.
Both halves: that is the whole confusion, concentration and syringe scale together. The syringe is honest. It cannot know your concentration or its own scale; that part is yours.
How many units is 2.4mg of semaglutide?
The short answer: it depends on the concentration. At 5mg per mL (a 5mg vial plus 1mL of water), 2.4mg reads as 48 units on a U-100 syringe. At 10mg per mL (a 10mg vial plus 1mL), 2.4mg reads as 24 units.
The rule: there is no single units number for any milligram amount. Concentration first, syringe type second, then the math, or use the calculator above.
What's not known yet?
The status: semaglutide is FDA approved under brand names: Ozempic for type 2 diabetes, Wegovy for weight management and cardiovascular risk reduction, Rybelsus as oral tablets for type 2 diabetes. Verified against the current labels, July 2026.
What moved recently: an oral Wegovy pill (25mg daily) was approved in December 2025, and a higher-dose Wegovy HD pen (7.2mg weekly) in March 2026. The Wegovy label now also covers MASH, and the Ozempic label covers kidney-risk reduction in type 2 diabetes.
The key distinction: the approvals cover the brand pens, prefilled syringes, and tablets, fixed-dose products made by the manufacturer. Research-grade vials are not the approved product.
The regulatory line: FDA declared the semaglutide shortage resolved in February 2025, and compounding of copycat versions is now restricted to narrow conditions. FDA has also warned companies selling semaglutide labeled "for research purposes": products of unknown quality, sold outside the approval system entirely.
The real gaps:
- The obesity trials we pulled top out at 104 weeks (STEP 5), and SELECT's mean follow-up was 39.8 months, as of our 20 July 2026 check.
- In the STEP 1 extension cohort, stopping meant regaining: two-thirds of the lost weight came back within a year. What years of on-again, off-again use do is not in the literature we pulled.
- No verified data on the community vial patterns that dominate online discussion, as of our 20 July 2026 check. None of those patterns has been studied in a controlled trial.
As of that check, anyone saying different is guessing.
The biggest gap: in our read, a single gap matters more than any number above. A research-grade vial carries no independent verification of what is in it.
All taken on trust: identity, purity, sterility, and the real concentration on the label.
The quiet one: a mislabeled vial breaks every units calc on this page. The arithmetic is only as good as the concentration it starts from.
The real worry: that is not a question of dose, a question of source, and that is the one that would worry us before any unit count.
How this page is sourced
No secondary summaries: every trial figure on this page comes straight from the cited papers' abstracts. Nothing here comes from a summary page.
The regulatory documents: the approval status, escalation schedule, and FDA compounding position were checked against the current Wegovy and Ozempic labels (DailyMed) and two FDA pages, all pulled live 19 July 2026.
The six sources: below, with their DOIs and PubMed IDs. Pull them yourself; check the numbers on this page against theirs.
The standard: the site's sourcing and citation-verification standard lives on the methodology page. Any number here that ever gets corrected gets corrected there first.
Last reviewed: 19 July 2026.
-
1
Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183. PMID 33567185.
-
2
Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984. doi:10.1016/S0140-6736(21)00213-0. PMID 33667417.
-
3
Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. doi:10.1038/s41591-022-02026-4. PMID 36216945.
-
4
Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. doi:10.1111/dom.14725. PMID 35441470.
-
5
Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. doi:10.1056/NEJMoa1607141. PMID 27633186.
-
6
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563. PMID 37952131.
The disclaimer
Every page is reviewed by medical professionals before it ships, and written with longtime biohackers who were doing this before it was a trend. Reviewed still does not mean prescribed: nothing here is medical advice.
It is research, trial data, and reported use, with the numbers intact so you can check them. For decisions about your body, see a doctor who can look at your labs.
The weekly briefing
Get the next dosage guide.
New compound guides, new calculators, and the math behind the next panic post. One clear email a week.
Education only, never medical advice. Unsubscribe anytime.